Targeting affective cognition during pregnancy to prevent postpartum depression: a randomized controlled trial with...

Postpartum depression (PPD) affects approximately 17% of women globally and is predicted by prior mental illness and socioeconomic disadvantage. Emerging evidence suggests that negative bias in the cognitive processing of infant cues and heightened reactivity to infant distress during pregnancy contribute to PPD risk and may thus represent a treatment target. This randomized controlled trial examined whether prenatal affective cognitive training (PACT) reduces PPD risk by modulating negative biases in pregnant women at heightened risk. Of 280 women assessed, 147 at heightened risk were randomized to PACT or care as usual (CAU). PACT comprised five individualized 90-minute sessions over five weeks, combining computerized and virtual-reality tasks targeting negative cognitive bias, attentional bias, emotion regulation, and working memory in response to infant stimuli. Affective cognition was assessed at baseline and post-intervention; mood was rated at baseline, post-intervention, and weekly for six weeks after birth. Diagnostic interviews (Present State Examination) were conducted six months postpartum. The primary outcome was PPD incidence within six months postpartum; secondary outcomes included depressive symptoms over the first six weeks and changes in affective cognition. Follow-up data were available for 121 (83%) participants (PACT n = 54; CAU n = 67). PACT did not significantly reduce PPD overall (p = 0.18) or depressive symptoms (p = 0.31) but increased positive interpretation of infant emotions (p = 0.003). Exploratory analyses indicated lower PPD incidence among multiparous participants receiving PACT than CAU (5% vs. 35%; OR=0.10, 95% CI [0.01-0.92], p = 0.04) and additional parity-specific changes in affective cognition. These exploratory findings require replication in larger trials. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov with Trial number NCT06046456 on 21 September 2023 https://clinicaltrials.gov/study/NCT06046456.